Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Corp. Communications | November 17, 2014 | November 19, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date November 17, 2014 · Filed November 19, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,350 |
Reported balance
After 2014-11-17 transaction · row 1
1 source rowRow 1 · 2014-11-17 · Sale · Disposed 33 · Balance 43,350 F1: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2014 Filed Nov 19, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 33 | $111.93 | $3,693.69 |
DisclosureSEC source: 0001209191-14-069991 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,350 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 30, 2014 Filed Nov 3, 2014 22:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,000 | $0.01 | $200.00 |
DisclosureSEC source: 0001209191-14-065912 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,350 F1 · shares: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on October 30, 2017 (or, if later, the day following the earnings release for the third quarter of 2017) if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 6,875 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · derivative · entry 18 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,125 Underlying: Common Stock · 6,875 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 6,875 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · derivative · entry 17 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 6,875 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 17,157 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · derivative · entry 16 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,593 Underlying: Common Stock · 17,157 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · derivative · entry 15 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 3,532 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · derivative · entry 14 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,218 Underlying: Common Stock · 3,532 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,625 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · derivative · entry 13 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 5,625 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/13/2011. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,172 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · derivative · entry 12 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,344 Underlying: Common Stock · 1,172 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2011. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,629 | $113.90 | $1,324,543.10 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 11 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,350 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $113.90 (range $113.62 to $114.32). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,400 | $113.08 | $1,741,432.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 10 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,979 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $113.08 (range $112.61 to $113.59). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 21,881 | $112.21 | $2,455,267.01 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 9 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,379 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.21 (range $111.61 to $112.60). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,576 | $111.32 | $843,360.32 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 8 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,260 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.32 (range $110.61 to $111.60). F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,875 | $77.31 | $531,506.25 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 7 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,875 | $83.36 | $573,100.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 6 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 17,157 | $45.11 | $773,952.27 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 5 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 15,250 | $48.74 | $743,285.00 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 4 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,532 | $37.86 | $133,721.52 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 3 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,625 | $51.75 | $291,093.75 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,172 | $38.80 | $45,473.60 |
DisclosureSEC source: 0001209191-14-060592 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2014 Filed Jul 17, 2014 22:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 27,500 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-14-047903 · doc4.xml · derivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2024-07-14 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/15/2014. Read SEC document |
| June 24, 2014 Filed Jun 26, 2014 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (righty to buy) · Derivative | 5,234 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-14-043875 · doc4.xml · derivative · entry 5 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,516 Underlying: Common Stock · 5,234 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 2/3/2011. Read SEC document |
| June 24, 2014 Filed Jun 26, 2014 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $37.29 | $0.00 |
DisclosureSEC source: 0001209191-14-043875 · doc4.xml · derivative · entry 4 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2020-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 24, 2014 Filed Jun 26, 2014 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,734 | $98.03 | $1,248,314.02 |
DisclosureSEC source: 0001209191-14-043875 · doc4.xml · nonDerivative · entry 3 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,350 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 24, 2014 Filed Jun 26, 2014 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,234 | $38.80 | $203,079.20 |
DisclosureSEC source: 0001209191-14-043875 · doc4.xml · nonDerivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2014 Filed Jun 26, 2014 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $37.29 | $279,675.00 |
DisclosureSEC source: 0001209191-14-043875 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2014 Filed May 19, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 22 | $67.00 | $1,474.00 |
DisclosureSEC source: 0001209191-14-035067 · doc4.xml · nonDerivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,350 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 15, 2014 Filed May 19, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 347 | $65.57 | $22,752.79 |
DisclosureSEC source: 0001209191-14-035067 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,372 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $65.57 (range $65.22 to $66.09). F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2014 Filed May 6, 2014 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $69.42 | $6,942.00 |
DisclosureSEC source: 0001209191-14-031519 · doc4.xml · nonDerivative · entry 3 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,350 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2014 Filed May 6, 2014 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $67.94 | $27,176.00 |
DisclosureSEC source: 0001209191-14-031519 · doc4.xml · nonDerivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,450 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $67.94 (range $67.73 to $68.24). Read SEC document |
| May 02, 2014 Filed May 6, 2014 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $67.01 | $33,505.00 |
DisclosureSEC source: 0001209191-14-031519 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,850 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $67.01 (range $66.49 to $67.40). Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008357 · doc4.xml · derivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 14,250 | $0.01 | $142.50 |
DisclosureSEC source: 0001209191-14-008357 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,350 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| January 21, 2014 Filed Jan 23, 2014 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,250 | $85.00 | $106,250.00 |
DisclosureSEC source: 0001209191-14-004556 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 06, 2014 Filed Jan 8, 2014 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 838 | $75.00 | $62,850.00 |
DisclosureSEC source: 0001209191-14-002375 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,350 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 12, 2013 Filed Dec 12, 2013 22:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,083 | $65.48 | $332,834.84 |
DisclosureSEC source: 0001209191-13-056699 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,188 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $65.48 (range $65.05 to $65.91). F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 93 | $60.97 | $5,670.21 |
DisclosureSEC source: 0001209191-13-053085 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,271 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 27,500 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-13-038692 · doc4.xml · derivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2023-07-29 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| July 12, 2013 Filed Jul 15, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-13-036628 · doc4.xml · derivative · entry 7 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 5,000 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2011. Read SEC document |
| July 12, 2013 Filed Jul 15, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $86.00 | $430,000.00 |
DisclosureSEC source: 0001209191-13-036628 · doc4.xml · nonDerivative · entry 5 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,271 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 12, 2013 Filed Jul 15, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 678 | $85.00 | $57,630.00 |
DisclosureSEC source: 0001209191-13-036628 · doc4.xml · nonDerivative · entry 4 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,271 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 12, 2013 Filed Jul 15, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $38.80 | $194,000.00 |
DisclosureSEC source: 0001209191-13-036628 · doc4.xml · nonDerivative · entry 3 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2013 Filed Jul 15, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-13-036628 · doc4.xml · derivative · entry 6 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 5,000 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2011. Read SEC document |
| July 11, 2013 Filed Jul 15, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $84.00 | $420,000.00 |
DisclosureSEC source: 0001209191-13-036628 · doc4.xml · nonDerivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 11, 2013 Filed Jul 15, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $38.80 | $194,000.00 |
DisclosureSEC source: 0001209191-13-036628 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2013 Filed Jul 10, 2013 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 3,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-13-036102 · doc4.xml · derivative · entry 7 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,750 Underlying: Common Stock · 3,500 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| July 08, 2013 Filed Jul 10, 2013 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 22,500 | $0.00 Strike: $37.29 | $0.00 |
DisclosureSEC source: 0001209191-13-036102 · doc4.xml · derivative · entry 6 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 22,500 shares Expires 2020-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 05/10/2010. Read SEC document |
| July 08, 2013 Filed Jul 10, 2013 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,100 | $82.46 | $338,086.00 |
DisclosureSEC source: 0001209191-13-036102 · doc4.xml · nonDerivative · entry 5 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $82.46 (range $82.03 to $82.70). Read SEC document |
| July 08, 2013 Filed Jul 10, 2013 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,400 | $81.54 | $277,236.00 |
DisclosureSEC source: 0001209191-13-036102 · doc4.xml · nonDerivative · entry 4 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,049 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $81.54 (range $81.04 to $81.88). Read SEC document |
| July 08, 2013 Filed Jul 10, 2013 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 21,203 | $80.48 | $1,706,417.44 |
DisclosureSEC source: 0001209191-13-036102 · doc4.xml · nonDerivative · entry 3 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,449 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $80.48 (range $80.04 to $80.91). F3 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.